Gemcitabine treatment with HER2/neu vaccine and antiglucocorticoid-induced tumor necrosis factor receptor (TNFR) family-related receptor (GITR) antibody is effective in HER2/neu-positive tumor [123], in which gemcitabine attenuates the tumor immune suppression through dramatic reduction of MDSCs. The gene discussed is TNFRSF18; the disease is neoplasm.